skip to Main Content

LED Medical Diagnostics Inc. Announces Assignment of Dr. David Morgan as Chief Technology Officer for Subsidiary LED Dental Inc.

  • January 30, 2014
  • News Releases

BURNABY, British Columbia – January 30, 2014 – LED Medical Diagnostics Inc. (“LED Medical” or the “Company”) announced today that Dr. David Morgan, previously Chief Science Officer for LED Dental Inc., has transitioned to Chief Technology Officer for LED Dental Inc., LED Medical’s wholly-owned operating subsidiary responsible for the manufacture and distribution of the VELscope® Vx product line.

“Dr. Morgan’s work was instrumental in the design, development and commercialization of our VELscope® Vx family of products,” states Dr. David Gane, CEO of LED Medical. “We are committed to our role as the industry leader in adjunctive devices based on tissue fluorescence visualization. With this new position, Dr. Morgan will be able to focus all of his expertise towards ongoing innovation and line expansion for our award-winning VELscope® technology.”

LED Medical is also pleased to report that Peter Whitehead, previously CEO of the company prior to the appointment of Dr. David Gane in 2013, will maintain a role in the company as a board director. Mr. Whitehead’s early cancer research on cell death and cardiac rejection is the cornerstone of LED Medical. In 2000, Mr. Whitehead and a British Columbia Cancer Agency (BCCA) researcher were awarded a patent for endoscopes and methods relating to direct viewing of target tissue. Mr. Whitehead subsequently formed a separate company and acquired this patent as well as another patent relating to a fluorescence scope system for dermatologic diagnosis with the understanding that, together, they provided significant relevance for the detection of oral cancer as well as cervical cancer. This led to the ground-breaking work on a commercially viable technology platform ultimately marketed under the name VELscope®.

About VELscope® Vx Enhanced Oral Assessment

The distinctive blue-spectrum light of the VELscope® Vx hand-held device causes the soft tissues of the mouth to naturally fluoresce. Healthy tissues fluoresce in distinct patterns that are visibly disrupted by trauma or disease, such as neoplastic lesions, chemical irritation, side-effects from medication, thermal damage, fungal, viral or bacterial infections. Use of the VELscope® Vx allows a wide variety of oral abnormalities to be discovered, often before they’re visible to the unassisted eye. It is also the only tissue fluorescence device with photo/video documentation capabilities through the viewing mechanism, a key function for referrals and patient records.

Today VELscope® devices are used to conduct more examinations for oral cancer and other oral diseases than any other adjunctive device. To date, more than 12,000 VELscope® systems are in use globally and dental practitioners have performed more than 25 million exams.

About LED Medical Diagnostics Inc.

Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc. is a leading developer of LED-based visualization technologies for the medical industry. The Company is currently listed on the Toronto Stock Exchange (TSX-V) under the symbol “LMD”, the OTCQX under the symbol “LEDIF”, as well as the Frankfurt Stock Exchange under the symbol “LME”. For more information, visit www.ledmd.com.

Through its wholly-owned subsidiary, LED Dental Inc., the company manufactures the VELscope® Vx Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. VELscope® Vx devices are now used to conduct more examinations for oral cancer and other oral diseases than any other adjunctive device. For more information, call 604.434.4614 or visit www.leddental.com.

This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding the innovation and potential expansion of the Company’s technology to other medical application. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation”s actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, and product development risks such as regulatory, design, intellectual property and other factors described in the Corporation”s reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2012. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

Back To Top